NFE2L2 and Parkinson disease: Furthermore, Lastres-Becker et al. [141] provided a compelling rationale for targeting NRF2 with dimethyl fumarate as a therapeutic strategy to reinforce endogenous brain defense mechanisms against PD-associated synucleinopathy.